Skip to Content Facebook Feature Image

41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People

Business

41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People
Business

Business

41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People

2025-05-23 21:00 Last Updated At:21:15

TOKYO, May 23, 2025 /PRNewswire/ -- The 41st WHO Sasakawa Health Prize was presented to Danish psychiatrist Dr. Merete Nordentoft in recognition of her work on suicide prevention in young people, during a ceremony at the 78th World Health Assembly in Geneva on May 23.

The award highlights a science- and practice-based strategy for tackling the serious public health issue of suicide, which kills more than 700,000 people worldwide every year and is one of the leading causes of death among 15- to 29-year-olds.

Dr. Nordentoft's approach to suicide prevention and early intervention in psychosis, particularly among young people, has produced striking results. It has been implemented throughout Denmark and is considered a model for other countries.

In 1998, she launched the OPUS Outreach Treatment Program, an early intervention program for first-time psychiatric patients aged 18 to 45. The program is based on a multidisciplinary team offering weekly meetings with a primary staff member, recovery-oriented groups and family involvement. It has been recognized for reducing hospitalization rates and improving quality of life, as well as for its emphasis on the role of community and family.

The name OPUS ("work") is taken from the world of music and was chosen to express the need to orchestrate a carefully prepared plan in which the different elements of the program are in harmony with each other. OPUS aims to integrate psychiatric, psychological and social interventions where the interplay between them is crucial.

In accepting the award, Dr. Nordentoft said: "It is a privilege to stand here today—not only for myself, but for the young people with psychosis, their families and the colleagues who have made this journey possible."  The award, she said, "gives voice to those young people—and reinforces that with the right support, early enough, recovery is not only possible—it is likely."

The award ceremony was attended by WHO Director-General Dr. Tedros Adhanom Ghebreyesus and the prize was presented to Dr. Nordentoft by Yohei Sasakawa, chairman of The Nippon Foundation.

"This is the first time the prize has honored efforts in the field of mental health," said Sasakawa, "and Dr. Nordentoft's work is a pioneering practice, as the WHO's suicide prevention initiative, LIVE LIFE, emphasizes the importance of strengthening support and prevention measures at the local level, as well as a primary health care approach."

The prize money of US$30,000 will be used to host a conference that will bring together clinicians, researchers and patients to deepen discussions on optimizing treatments.

Sasakawa Health Prize

The Sasakawa Health Prize was established in 1984 upon the initiative and with funds provided by Ryoichi Sasakawa, then president of the Japan Shipbuilding Foundation (now The Nippon Foundation) and president of Sasakawa Memorial Health Foundation (now Sasakawa Health Foundation), and with the agreement of WHO Director-General Dr. Halfdan Mahler, with the aim of contributing to the realization of WHO's "Health for All" philosophy. The award recognizes individuals and organizations that have made significant contributions to improving people's health and well-being through sustainable and effective activities, such as the promotion of primary health care and specific health programs at the local level.

Sasakawa Health Foundation

Sasakawa Health Foundation was established in 1974 by Ryoichi Sasakawa (1899 – 1995), founder of The Nippon Foundation, and Professor Morizo Ishidate (1901 – 1996), the father of leprosy chemotherapy in Japan, for the purpose of eradicating leprosy from the world. Since its establishment, the foundation has maintained its focus on leprosy while also engaging in activities to combat parasitic diseases and HIV/AIDS, providing medical cooperation following the Chernobyl nuclear accident, developing human resources in the field of international health, and improving hospice palliative care. The foundation currently focuses its work on leprosy control and the promotion of community health. It is engaged in a variety of projects both in Japan and overseas, based on the principle of "Better Health and Dignity for All."

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People

41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles